Hims & Hers Health, Inc. (HIMS) Tops Q4 EPS by 3c, Offers Guidance

Hims & Hers Health, Inc. (NYSE: HIMS) reported Q4 EPS of $0.08, $0.03 better than the analyst estimate of $0.05. Revenue for the quarter came in at $617.8 million versus the consensus estimate of $618.73 million.

GUIDANCE:

Hims & Hers Health, Inc. sees FY2026 revenue of $2.7-2.9 billion, versus the consensus of $2.75 billion.

• Adjusted EBITDA of $300 million to $375 million

Hims & Hers Health, Inc. sees Q1 2026 revenue of $600-625 million, versus the consensus of $653.9 million.

Adjusted EBITDA of $35 million to $55 million

For earnings history and earnings-related data on Hims & Hers Health, Inc. (HIMS) click here.

You May Also Be Interested In

• Hertz cuts guidance, announces notes and stock offerings, shares sink
• OneSpan names two go-to-market executives in marketing and alliances
• Oracle Health and Theator partner on AI surgical documentation tools